news_6

Qraft Technologies Closes US$146 Million Investment from SoftBank Group Entering into a Strategic Partnership to Accelerate AI in the Asset Management Industry

SEOUL, South Korea--(BUSINESS WIRE)--#ai--AI enabled fintech company Qraft Technologies, Inc. (“Qraft” or “the company”) today announced that it has closed...

news_6

Research Report on China’s Mecapegfilgrastim Market, 2021-2025 Featuring Jiangsu Hengrui Medicine Co., Ltd. (Aiduo) – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Research Report on China's Mecapegfilgrastim Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the market...

news_6

India Railway Public Private Partnership Opportunities 2021-2025: Tracking New Avenues of Investments for Railway Infrastructure Developments – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Examining PPP Opportunities Across Indian Railways - Tracking New Avenues of Investment Opportunity for Railways Infrastructure Development Till...

news_6

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

DANVERS, Mass.--(BUSINESS WIRE)--Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute...

news_6

o9 Solutions and AWS Collaborate to Help Businesses Accelerate the Digital Transformation of Their Supply Chain Planning and Execution Processes

DALLAS--(BUSINESS WIRE)--o9 Solutions, a leading enterprise artificial intelligence (AI) software platform provider for transforming planning and decision-making, today announced joining...

news_6

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--#autoimmune--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”),...

news_6

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--#MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”),...